3MacDonald TT, Monteleone G, Pender SL. Recent developments in the immunology of inflammatory bowel disease. Scand J Immunol, 2000, 51:
4～9.2.Kitani A, Fuss IJ, Nakamura K, Schwartz OM,Usui T, Strober W. Treatment of experimental(Trinitrobenzene sulfonic acid) colitis by intranasal administration of transforming growth factor(TGF)-betal plasmid: TGF-betal-mediated suppression of T helper cell type i response occurs by interleukin (IL)-10 induction and IL-12 receptorbeta2 chain downregulation. J Exp Med, 2000,192: 41～52.
5Das KM, Dasgupta A, Mandal A, Geng X. Autoimmunity to cytoskeletal protein tropomyosin. Aclue to the pathogenetic mechanism for ulcerative colitis. J Immunol, 1993, 150: 2487～2493.
6Biancone L, Mandal A, Yang H, Dasgupta T, Paoluzi AO, Marcheggiano A, Paoluzi P, Pallone F,Das KM. Production of immunoglobulin G and G1antibodies to cytoskeletal protein by lamina propria cells in ulcerative colitis. Gastroenterology,1995, 109: 3～12.
7Rogler G, Brand K, Vogl D, Page S, Hofmeister R,Andus T, Knuechel R, Baeuerle PA, ScholmerichJ, Gross V. Nuclear factor kappaB is activated inmacrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology, 1998, 115: 357～369.
8Schreiber S, Nikolaus S, Hampe J. Activation ofnuclear factor kappa B inflammatory bowel disease. Gut, 1998, 42: 477～484.
9Jones SC, Evans SW, Lobo AJ, Ceska M, AxonAT, Whicher JT. Serum interleukin-8 in inflammatory bowel disease. J Gastroenterol Hepatol,1993, 8: 508～512.
10Keshavarzian A, Fusunyan RD, Jacyno M, Winship D, MacDermott RP, Sanderson IR. Increasedinterleukin-8 (IL-8) in rectal dialysate from patients with ulcerative colitis: evidence for a biological role for IL-8 in inflammation of the colon.Am J Gastroenterol, 1999, 94: 704～712.
